PE20180329A1 - METHODS TO DIAGNOSE AND TREAT CANCER - Google Patents
METHODS TO DIAGNOSE AND TREAT CANCERInfo
- Publication number
- PE20180329A1 PE20180329A1 PE2017002516A PE2017002516A PE20180329A1 PE 20180329 A1 PE20180329 A1 PE 20180329A1 PE 2017002516 A PE2017002516 A PE 2017002516A PE 2017002516 A PE2017002516 A PE 2017002516A PE 20180329 A1 PE20180329 A1 PE 20180329A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- subject
- cancer
- ntrk2
- ntrk1
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 7
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 abstract 4
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 abstract 4
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 abstract 4
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 abstract 4
- 230000035772 mutation Effects 0.000 abstract 4
- 108010064892 trkC Receptor Proteins 0.000 abstract 4
- 102100029166 NT-3 growth factor receptor Human genes 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 201000005179 adrenal carcinoma Diseases 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 230000001054 cortical effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000000508 neurotrophic effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta referido una serie de mutaciones puntuales diferentes en los genes: receptor de tirosina cinasa neurotrofico de tipo: NTRK1, NTRK2 y NTRK3 en muestras de biopsia de sujetos que tenian una serie de diferentes canceres. Tambien se proporcionan metodos para tratar a un sujeto que tenga cancer, metodos para seleccionar un tratamiento que incluya una cantidad terapeuticamente eficaz de un inhibidor de cinasa relacionada con tropomiosina (Trk) para un sujeto, metodos para determinar la probabilidad de que un sujeto que tiene un cancer tendra una respuesta positiva al tratamiento con un inhibidor de Trk, metodos para predecir la eficacia de un inhibidor de Trk en un sujeto que tiene un cancer, metodos para determinar el riesgo de que un sujeto desarrolle un cancer y metodos para ayudar en el diagnostico del cancer que estan basados en la identificacion de un sujeto que tiene una celula que tiene al menos una de las mutaciones puntuales en los genes NTRK1, NTRK2 y/o NTRK3 o en la determinacion de que el sujeto tiene una celula que tiene al menos una de las mutaciones puntuales en NTRK1, NTRK2 y/o NTRK3. Tambien se proporcionan kits que permiten la deteccion de al menos una de las mutaciones puntuales en NTRK1, NTRK2 y/o NTRK3. En donde el cancer se selecciona entre adenocarcinoma, carcinoma cortical de glandulas suprarrenales, entre otros.A number of different point mutations are reported in the genes: neurotrophic receptor tyrosine kinase of the type: NTRK1, NTRK2 and NTRK3 in biopsy samples from subjects who had a number of different cancers. Also provided are methods of treating a subject having cancer, methods of selecting a treatment that includes a therapeutically effective amount of a tropomyosin-related kinase (Trk) inhibitor for a subject, methods of determining the likelihood that a subject having a cancer will have a positive response to treatment with a Trk inhibitor, methods to predict the efficacy of a Trk inhibitor in a subject who has cancer, methods to determine the risk that a subject will develop a cancer, and methods to aid in the cancer diagnoses that are based on the identification of a subject who has a cell that has at least one of the point mutations in the NTRK1, NTRK2 and / or NTRK3 genes or on the determination that the subject has a cell that has at least one of the point mutations in NTRK1, NTRK2 and / or NTRK3. Kits are also provided that allow the detection of at least one of the point mutations in NTRK1, NTRK2 and / or NTRK3. Where the cancer is selected from adenocarcinoma, cortical carcinoma of the adrenal glands, among others.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169443P | 2015-06-01 | 2015-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180329A1 true PE20180329A1 (en) | 2018-02-13 |
Family
ID=56194562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002516A PE20180329A1 (en) | 2015-06-01 | 2016-06-01 | METHODS TO DIAGNOSE AND TREAT CANCER |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180140604A1 (en) |
| EP (2) | EP3722441A1 (en) |
| JP (1) | JP2018526324A (en) |
| KR (1) | KR20180021745A (en) |
| CN (1) | CN107849615A (en) |
| AU (1) | AU2016270803A1 (en) |
| BR (1) | BR112017025773A2 (en) |
| CA (1) | CA2988423A1 (en) |
| CL (1) | CL2017003069A1 (en) |
| EA (1) | EA201792679A1 (en) |
| HK (1) | HK1253093A1 (en) |
| IL (1) | IL256025A (en) |
| MA (2) | MA44936A1 (en) |
| MX (1) | MX2017015461A (en) |
| PE (1) | PE20180329A1 (en) |
| PH (1) | PH12017502200A1 (en) |
| SV (1) | SV2017005577A (en) |
| TN (1) | TN2017000502A1 (en) |
| WO (1) | WO2016196671A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| AU2009308465B2 (en) | 2008-10-22 | 2015-02-12 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors |
| AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| DK2918588T3 (en) | 2010-05-20 | 2017-08-28 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR20180102544A (en) | 2015-10-26 | 2018-09-17 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | TRK Inhibitors - Point Mutation in Resistant Cancer and Related Methods |
| BR112018012255A2 (en) * | 2015-12-18 | 2018-12-04 | Ignyta Inc | method to treat cancer |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| NZ747135A (en) | 2016-04-04 | 2025-05-02 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| RS61463B1 (en) | 2016-05-18 | 2021-03-31 | Loxo Oncology Inc | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
| JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
| IL271759B2 (en) | 2017-07-19 | 2024-01-01 | Ignyta Inc | Pharmaceutical compositions comprising entrectinib |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
| MA50456A (en) * | 2017-10-26 | 2020-09-02 | Array Biopharma Inc | MACROCYCLIC KINASE TRK INHIBITOR FORMULATIONS |
| CN109055562B (en) * | 2018-10-29 | 2022-12-20 | 深圳市颐康生物科技有限公司 | Biomarker and method for predicting recurrence and death risk of renal cell carcinoma |
| US20220243280A1 (en) * | 2019-05-24 | 2022-08-04 | Foundation Medicine, Inc. | Ntrk fusion molecules and uses thereof |
| CN110643672A (en) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | Medical application of high-expression TrkB as novel target point in inhibiting pancreatic cancer metastasis |
| KR20220008175A (en) * | 2020-07-13 | 2022-01-20 | 가톨릭대학교 산학협력단 | Stage-specific markers for diagnosing prognosis and determining treatment stratagies of patient of Prostate adenocarcinoma |
| CN112779147A (en) * | 2020-12-23 | 2021-05-11 | 广西大学 | Method and device for measuring micro mass transfer and biochemical reaction process of microorganism aggregate in fluidized state |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| NZ523105A (en) | 2000-06-22 | 2004-07-30 | Genentech Inc | Agonist anti-trk-C monoclonal antibodies |
| WO2004082458A2 (en) * | 2003-02-21 | 2004-09-30 | The Johns Hopkins University | Tyrosine kinome |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| DE102005003687A1 (en) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample |
| WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ITRM20050290A1 (en) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
| BRPI0615277A2 (en) | 2005-08-25 | 2009-08-04 | Creabilis Therapeutics Spa | k-252a polymer conjugate, pharmaceutical composition comprising said conjugate as well as use thereof |
| AU2008247442B2 (en) | 2007-05-04 | 2013-01-10 | Irm Llc | Compounds and compositions as c-kit and PDGFR kinase inhibitors |
| EP2176231B1 (en) | 2007-07-20 | 2016-10-19 | Nerviano Medical Sciences S.r.l. | Substituted indazole derivatives active as kinase inhibitors |
| BRPI0817812A2 (en) | 2007-10-23 | 2015-04-14 | Novartis Ag | Use of trkb antibodies to treat respiratory disorders |
| US8642035B2 (en) | 2008-01-17 | 2014-02-04 | Irm Llc | Anti-TrkB antibodies |
| CN102105151B (en) | 2008-07-29 | 2013-12-18 | 内尔维阿诺医学科学有限公司 | Use of CDK inhibitor for treatment of glioma |
| CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| AU2009308465B2 (en) | 2008-10-22 | 2015-02-12 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors |
| WO2010058006A1 (en) | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor for the treatment of mesothelioma |
| AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| TWI619713B (en) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | Compounds and methods for kinase regulation and their indications |
| DK2918588T3 (en) | 2010-05-20 | 2017-08-28 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| MX2013009767A (en) | 2011-02-25 | 2013-10-01 | Irm Llc | Compounds and compositions as trk inhibitors. |
| SMT201700035T1 (en) | 2011-05-13 | 2017-03-08 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| RU2014119150A (en) | 2011-11-14 | 2015-12-27 | Тесаро, Инк. | MODULATION OF SOME TYROZINKINASES |
| US9242977B2 (en) | 2012-04-26 | 2016-01-26 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| JP2013226108A (en) * | 2012-04-27 | 2013-11-07 | Astellas Pharma Inc | Method for detecting new ntrk2 activating mutation |
| AU2013265288B2 (en) | 2012-05-23 | 2017-12-21 | Nerviano Medical Sciences S.R.L. | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| TWI585088B (en) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | Imidazo[1,2-b]indole derivatives as kinase inhibitors |
| JP2014082984A (en) * | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | Method for detecting novel ntrk2 activating mutation |
| US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
| KR102181915B1 (en) | 2012-11-13 | 2020-11-23 | 어레이 바이오파마 인크. | N-pyrrolidinyl, n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| CN106986857B (en) | 2013-02-19 | 2019-07-05 | 小野药品工业株式会社 | Trk inhibiting compound |
| US10407509B2 (en) | 2013-07-30 | 2019-09-10 | Blueprint Medicines Corporation | NTRK2 fusions |
| CN110317214B (en) | 2014-01-24 | 2022-11-22 | 特普医药公司 | Diaryl macrocycles as modulators of protein kinases |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| SMT201900522T1 (en) | 2014-05-15 | 2019-11-13 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| CN106573913B (en) | 2014-08-18 | 2019-11-19 | 小野药品工业株式会社 | Inhibit the acid-addition salts of the compound of Trk |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
-
2016
- 2016-06-01 MA MA44936A patent/MA44936A1/en unknown
- 2016-06-01 MX MX2017015461A patent/MX2017015461A/en unknown
- 2016-06-01 CN CN201680042764.4A patent/CN107849615A/en active Pending
- 2016-06-01 US US15/579,007 patent/US20180140604A1/en not_active Abandoned
- 2016-06-01 HK HK18112480.2A patent/HK1253093A1/en unknown
- 2016-06-01 MA MA41667A patent/MA41667A1/en unknown
- 2016-06-01 PE PE2017002516A patent/PE20180329A1/en unknown
- 2016-06-01 EP EP20166281.4A patent/EP3722441A1/en not_active Withdrawn
- 2016-06-01 EP EP16731698.3A patent/EP3303631A1/en not_active Withdrawn
- 2016-06-01 CA CA2988423A patent/CA2988423A1/en not_active Abandoned
- 2016-06-01 WO PCT/US2016/035327 patent/WO2016196671A1/en active Application Filing
- 2016-06-01 TN TNP/2017/000502A patent/TN2017000502A1/en unknown
- 2016-06-01 AU AU2016270803A patent/AU2016270803A1/en not_active Abandoned
- 2016-06-01 JP JP2017563045A patent/JP2018526324A/en active Pending
- 2016-06-01 KR KR1020177037924A patent/KR20180021745A/en not_active Withdrawn
- 2016-06-01 EA EA201792679A patent/EA201792679A1/en unknown
- 2016-06-01 BR BR112017025773A patent/BR112017025773A2/en not_active Application Discontinuation
-
2017
- 2017-11-30 IL IL256025A patent/IL256025A/en unknown
- 2017-12-01 PH PH12017502200A patent/PH12017502200A1/en unknown
- 2017-12-01 SV SV2017005577A patent/SV2017005577A/en unknown
- 2017-12-01 CL CL2017003069A patent/CL2017003069A1/en unknown
-
2021
- 2021-11-23 US US17/533,823 patent/US20220088021A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016270803A1 (en) | 2018-01-04 |
| MA44936A1 (en) | 2021-09-30 |
| US20220088021A1 (en) | 2022-03-24 |
| HK1253093A1 (en) | 2019-06-06 |
| CN107849615A (en) | 2018-03-27 |
| CL2017003069A1 (en) | 2018-06-01 |
| WO2016196671A1 (en) | 2016-12-08 |
| JP2018526324A (en) | 2018-09-13 |
| CA2988423A1 (en) | 2016-12-08 |
| MX2017015461A (en) | 2018-08-15 |
| KR20180021745A (en) | 2018-03-05 |
| US20180140604A1 (en) | 2018-05-24 |
| BR112017025773A2 (en) | 2018-08-14 |
| SV2017005577A (en) | 2018-04-17 |
| EA201792679A1 (en) | 2018-06-29 |
| EP3722441A1 (en) | 2020-10-14 |
| TN2017000502A1 (en) | 2019-04-12 |
| PH12017502200A1 (en) | 2018-06-11 |
| IL256025A (en) | 2018-01-31 |
| EP3303631A1 (en) | 2018-04-11 |
| MA41667A1 (en) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180329A1 (en) | METHODS TO DIAGNOSE AND TREAT CANCER | |
| SV2018005677A (en) | PUNCTUAL MUTATIONS IN CANCER RESISTANT TO TRK AND METHODS RELATED TO THE SAME | |
| NZ732512A (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| MX2016010237A (en) | Methods of treating alzheimer's disease. | |
| MX2018008421A (en) | METHODS TO TREAT CANCER AND THE USE OF BIOMARKERS AS A PREDICATOR OF CLINICAL SENSITIVITY TO THERAPIES. | |
| EA201790716A1 (en) | USE OF FGFR MUTANT GENES PANELS TO DETECT ONCOLOGICAL PATIENTS THAT WILL BE USED FOR FGFR INHIBITOR TREATMENT | |
| MX392671B (en) | PD-L1-BINDING ANTAGONISTS AND THEIR USES FOR CANCER TREATMENT | |
| WO2016109782A3 (en) | Methods and compositions for detecting colorectal neoplasias | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX2017013777A (en) | METHOD FOR CANCER TREATMENT. | |
| BR112015023120A2 (en) | method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual | |
| MX386750B (en) | METHYLATION AND miRNA MARKERS FOR CANCER DETECTION. | |
| MX368099B (en) | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds. | |
| MX2024004195A (en) | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM. | |
| WO2015073896A3 (en) | Biomarkers for psma targeted therapy for prostate cancer | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| PE20160192A1 (en) | COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT | |
| EA201790549A1 (en) | PREDICTIVE AND PROGNOSTIC BIOMARKERS ASSOCIATED WITH ANTIANGIOGENIC TREATMENT OF MALIGNANT TUMOR | |
| EA201990730A1 (en) | RNA BIOMARKERS FOR HEREDITARY ANGIONEUROTIC Edema | |
| CY1122474T1 (en) | METHOD OF DIAGNOSIS OF TRIGEMIC NEURALGY | |
| AR104805A1 (en) | METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS | |
| EA201890816A1 (en) | OPTION 7AS ANDROGENOVA RECEPTOR AS A BIOMARKER FOR THE CHOICE OF TREATMENT OF PATIENTS WITH METASTATIC PROSTATE CANCER RESISTANT TO CASTRATION (MCRPC) | |
| WO2017095918A3 (en) | Methods for treating cancer using rspo3 antagonists |